Diversify Advisory Services LLC Invests $332,000 in Ascendis Pharma A/S (NASDAQ:ASND)

Diversify Advisory Services LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,991 shares of the biotechnology company's stock, valued at approximately $332,000.

A number of other institutional investors have also added to or reduced their stakes in ASND. HighTower Advisors LLC acquired a new position in Ascendis Pharma A/S during the fourth quarter worth $484,000. Corient Private Wealth LLC bought a new stake in Ascendis Pharma A/S during the fourth quarter worth about $450,000. American Century Companies Inc. lifted its position in Ascendis Pharma A/S by 17.5% during the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock worth $56,072,000 after purchasing an additional 60,548 shares during the period. LPL Financial LLC lifted its position in Ascendis Pharma A/S by 60.1% during the fourth quarter. LPL Financial LLC now owns 4,199 shares of the biotechnology company's stock worth $578,000 after purchasing an additional 1,577 shares during the period. Finally, Artisan Partners Limited Partnership lifted its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after purchasing an additional 39,309 shares during the period.

Ascendis Pharma A/S Stock Down 0.5%

Shares of NASDAQ ASND traded down $0.83 during trading on Thursday, reaching $169.31. The company had a trading volume of 147,974 shares, compared to its average volume of 482,383. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00. The stock has a market cap of $10.35 billion, a PE ratio of -26.80 and a beta of 0.38. The business's 50-day moving average is $169.96 and its 200 day moving average is $155.16.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. On average, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Oppenheimer reissued an "outperform" rating and set a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Wedbush raised their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada increased their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and a consensus price target of $223.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.